Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.

J Natl Cancer Inst 2016 Feb 7;108(2). Epub 2015 Nov 7.

: Edwin L. Steele Laboratories, Department of Radiation Oncology (VA, GBF, DPK, MB, RCS, GS, JK, TV, JDM, KN, DB, XQ, DGD, PH, DF, RKJ), Department of Pathology (MKS, EB), and Department of Medicine, Cancer Center (JAE), Massachusetts General Hospital and Harvard Medical School, Boston MA.

Background: Central nervous system (CNS) metastases represent a major problem in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer because of the disappointing efficacy of HER2-targeted therapies against brain lesions. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has shown efficacy in trastuzumab-resistant systemic breast cancer. Here, we tested the hypothesis that T-DM1 could overcome trastuzumab resistance in murine models of brain metastases.

Methods: We treated female nude mice bearing BT474 or MDA-MB-361 brain metastases (n = 9-11 per group) or cancer cells grown in organotypic brain slice cultures with trastuzumab or T-DM1 at equivalent or equipotent doses. Using intravital imaging, molecular techniques and histological analysis we determined tumor growth, mouse survival, cancer cell apoptosis and proliferation, tumor drug distribution, and HER2 signaling. Data were analyzed with one-way analysis of variance (ANOVA), Kaplan-Meier analysis, and Coefficient of Determination. All statistical tests were two-sided.

Results: T-DM1 delayed the growth of HER2-positive breast cancer brain metastases compared with trastuzumab. These findings were consistent between HER2-driven and PI3K-driven tumors. The activity of T-DM1 resulted in a survival benefit (median survival for BT474 tumors: 28 days for trastuzumab vs 112 days for T-DM1, hazard ratio = 6.2, 95% confidence interval = 6.1 to 85.84, P < .001). No difference in drug distribution or HER2-signaling was revealed between the two groups. However, T-DM1 led to a statistically significant increase in tumor cell apoptosis (one-way ANOVA for ApopTag, P < .001), which was associated with mitotic catastrophe.

Conclusions: T-DM1 can overcome resistance to trastuzumab therapy in HER2-driven or PI3K-driven breast cancer brain lesions due to the cytotoxicity of the DM1 component. Clinical investigation of T-DM1 for patients with CNS metastases from HER2-positive breast cancer is warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862418PMC
February 2016
82 Reads
12 Citations
12.583 Impact Factor

Publication Analysis

Top Keywords

breast cancer
20
her2-positive breast
12
t-dm1
9
t-dm1 overcome
8
cancer brain
8
cns metastases
8
cell apoptosis
8
drug distribution
8
brain lesions
8
brain metastases
8
ado-trastuzumab emtansine
8
her2-driven pi3k-driven
8
cancer
7
brain
7
trastuzumab
5
breast
5
determination statistical
4
pi3k-driven tumors
4
statistical tests
4
coefficient determination
4

References

(Supplied by CrossRef)
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline
J Clin Oncol 2014
Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis
Int J Radiat Oncol Biol Phys 2008
Multidisciplinary management of brain metastases
Oncologist 2007
Whole-brain radiation therapy in breast cancer patients with brain metastases
Nat Rev Clin Oncol 2010
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study
J Clin Oncol 2011
The biology of brain metastases-translation to new therapies
Nat Rev Clin Oncol 2011
Emerging strategies for treating brain metastases from breast cancer
Cancer Cell 2015
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
Cancer 2003
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
J Clin Oncol 2008
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
Clin Cancer Res 2009
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Lancet Oncol 2013

Similar Publications